RE: Could Hepatitis B Reactivation Be Overlooked in Patients with Resolved HBV Infection and Receiving Immunosuppressive Treatment?
作者信息
Han Pingyang, Wang Ziqiu, Wang Zhaohui
机构信息
Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University Faculty of Medicine, Shanghai, China
Department of Nephrology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
出版信息
Turk J Gastroenterol. 2024 Mar 31;35(4):352-353. doi: 10.5152/tjg.2024.235342.
Abstract
摘要
相似文献
1
RE: Could Hepatitis B Reactivation Be Overlooked in Patients with Resolved HBV Infection and Receiving Immunosuppressive Treatment?主题：乙肝病毒感染已康复且正在接受免疫抑制治疗的患者是否会被忽视乙肝病毒再激活？
Turk J Gastroenterol. 2024 Mar 31;35(4):352-353. doi: 10.5152/tjg.2024.235342.
2
Could Hepatitis B Reactivation be Overlooked in Patients with Resolved Hepatitis B Virus Infection and Receiving Immunosuppressive Treatment?乙型肝炎病毒感染者经治疗后病毒已清除，接受免疫抑制治疗时乙型肝炎再激活是否会被忽视？
Turk J Gastroenterol. 2024 Apr;35(4):350-351. doi: 10.5152/tjg.2024.23534.
3
Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.化疗或免疫抑制药物治疗期间的抗病毒预防，以防止HBV感染已治愈患者的HBV再激活：一项系统评价和荟萃分析。
Eur J Clin Pharmacol. 2018 Sep;74(9):1111-1119. doi: 10.1007/s00228-018-2487-4. Epub 2018 May 29.
4
Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.乙型肝炎病毒再激活管理策略的最新进展，针对风湿免疫科接受免疫抑制治疗的乙型肝炎病毒感染已缓解患者，以及新潟风湿中心的现状。
Mod Rheumatol. 2021 Jul;31(4):775-782. doi: 10.1080/14397595.2020.1832731. Epub 2020 Oct 29.
5
Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.需要免疫抑制治疗的乙肝病毒（HBV）感染患者中HBV再激活的特征、预防及管理
J Infect Dis. 2017 Nov 16;216(suppl_8):S778-S784. doi: 10.1093/infdis/jix178.
6
Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.接受化疗或免疫抑制治疗的乙肝病毒感染已康复患者中的乙肝病毒再激活
Eur J Gastroenterol Hepatol. 2018 Aug;30(8):925-929. doi: 10.1097/MEG.0000000000001130.
7
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.HBsAg 阳性的风湿性疾病患者在接受抗肿瘤坏死因子治疗或 DMARDs 治疗时乙型肝炎病毒再激活。
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
8
Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.血液淋巴增生性疾病患者乙型肝炎病毒再激活及其预防。
World J Gastroenterol. 2019 Jul 14;25(26):3299-3312. doi: 10.3748/wjg.v25.i26.3299.
9
American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的指南。
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.
10
A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.乙型肝炎病毒感染的风湿性疾病患者接受免疫抑制治疗的管理建议。
Mod Rheumatol. 2014 Jan;24(1):1-7. doi: 10.3109/14397595.2013.852834.
本文引用的文献
1
Could Hepatitis B Reactivation be Overlooked in Patients with Resolved Hepatitis B Virus Infection and Receiving Immunosuppressive Treatment?乙型肝炎病毒感染者经治疗后病毒已清除，接受免疫抑制治疗时乙型肝炎再激活是否会被忽视？
Turk J Gastroenterol. 2024 Apr;35(4):350-351. doi: 10.5152/tjg.2024.23534.
2
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients.接受皮质类固醇和常规合成免疫抑制剂治疗的肾病患者中已解决感染患者乙型肝炎病毒再激活的风险：单中心 258 例患者分析。
Turk J Gastroenterol. 2023 Oct;34(10):1035-1040. doi: 10.5152/tjg.2023.22511.
3
[Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)].《慢性乙型肝炎防治指南（2022年版）》
Zhonghua Gan Zang Bing Za Zhi. 2022 Dec 20;30(12):1309-1331. doi: 10.3760/cma.j.cn501113-20221204-00607.
4
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.亚太肝脏研究学会关于免疫抑制治疗相关乙型肝炎病毒再激活的临床实践指南。
Hepatol Int. 2021 Oct;15(5):1031-1048. doi: 10.1007/s12072-021-10239-x. Epub 2021 Aug 24.
5
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.2016 年全球乙型肝炎病毒感染的流行率、治疗和预防：一项建模研究。
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27.
6
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展：美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
7
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?美国食品药品监督管理局近期就免疫抑制药物和抗癌药物引发的乙型肝炎再激活发出警告：这只是冰山一角吗？
Hepatology. 2015 Feb;61(2):703-11. doi: 10.1002/hep.27609.
Zotero 插件